Recruiting Multiple Myeloma Studies in Buffalo
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatme...
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the contr...
About Multiple Myeloma Clinical Trials in Buffalo
Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.
There are currently 2 multiple myeloma clinical trials recruiting participants in Buffalo, NY. These studies are seeking a combined 574 participants. Research is being sponsored by Simcha IL-18, Inc., Sanofi. Clinical trial participation is free and participants receive study-related medical care at no cost.
Multiple Myeloma Clinical Trials in Buffalo — FAQ
Are there multiple myeloma clinical trials in Buffalo?
Yes, there are 2 multiple myeloma clinical trials currently recruiting in Buffalo, NY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Buffalo?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Buffalo research site will contact you about next steps.
Are clinical trials in Buffalo free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Buffalo studies also compensate for your time and travel.
What multiple myeloma treatments are being tested?
The 2 active trials in Buffalo are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.
Data updated March 2, 2026 from ClinicalTrials.gov